Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel scFv against Notch Ligand JAG1 Suitable for Development of Cell Therapies toward JAG1-Positive Tumors

2 Mar 2023

Abstract excerpt

The Notch signaling ligand JAG1 is overexpressed in various aggressive tumors and is associated with poor clinical prognosis. Hence, therapies targeting oncogenic JAG1 hold great potential for the treatment of certain tumors. Here, we report the identification of specific anti-JAG1 single-chain variable fragments (scFvs), one of them endowing chimeric antigen receptor (CAR) T cells with cytotoxicity against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to T-cell and B-cell Immunology
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36979394
DOI: 10.3390/biom13030459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel scFv against Notch Ligand JAG1 Suitable for Development of Cell Therapies toward JAG1-Positive TumorsPMID 36979394Read ↗

The Notch ligand Jagged1 as a target for anti-tumor therapySemantic proximity Read ↗

Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.Semantic proximity Read ↗

Generation and characterization of CD1d‐specific single‐domain antibodies with distinct functional featuresSemantic proximity Read ↗

NOTCH1 pathway: a molecular target in T-cell cancers?Semantic proximity Read ↗

A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytesSemantic proximity Read ↗

Targeting NOTCH1 in hematopoietic malignancy.Semantic proximity Read ↗

NOTCH1 drives immune-escape mechanisms in B cell malignanciesSemantic proximity Read ↗

Novel NOTCH1-unmutated T-ALL Cell Line With Suppressed Growth by Gamma-secretase Inhibitors.Semantic proximity Read ↗

Recent advances on NOTCH signaling in T-ALL.Semantic proximity Read ↗

Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy.Semantic proximity Read ↗

Notch Signaling Proteins: Legitimate Targets for Cancer TherapySemantic proximity Read ↗

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.